Key facts
- This page summarizes John David Finley's Form 4 filing for PALISADE BIO, INC. (PALI).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 Feb 2025, 17:56.
John David Finley - 11 Feb 2025 Form 4 Insider Report for PALISADE BIO, INC. (PALI)
- Reporting relationship
- CEO, CFO, Director
- Issuer ticker
- PALI
- Reported as of
- 11 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Feb 2025, 17:56:42 UTC
- Prior SEC filing
- 30 May 2024
- Next SEC filing
- 05 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ JD Finley
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John David Finley filed Form 4 for PALISADE BIO, INC. (PALI) on 13 Feb 2025.
Change
- Previous filing in this sequence was filed on 30 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PALI
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +47,000
- Change %
- Price
- $0.000000
- Shares after
- 47,000
- Date
- 11 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 47,000
- Exercise price
- $1.13
- Footnotes
- F1
PALI
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- Price
- $0.000000
- Shares after
- 40,000
- Date
- 11 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The shares subject to this option shall vest and become exercisable in twelve equal quarterly installments over a three-year period beginning on May 11, 2025, subject to the Reporting Person's continuous service through each such vesting date.
Footnote F2
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
Footnote F3
The RSUs shall vest in three equal annual installments beginning on February 11, 2026, subject to the Reporting Person's continuous service through each such vesting date.